Compare iShares MSCI Indonesia ETF (EIDO) vs Hinge Health Inc. Class A Common Stock (HNGE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
iShares MSCI Indonesia ETF vs Hinge Health Inc. Class A Common Stock — how do they compare? iShares MSCI Indonesia ETF trades at $11.83 (market cap $398.15M), while Hinge Health Inc. Class A Common Stock trades at $103.99 (market cap $8.47B). The key difference: Hinge Health Inc. Class A Common Stock is far larger — about 21.3× iShares MSCI Indonesia ETF's market cap, and Hinge Health Inc. Class A Common Stock is trading nearer its 52-week high, iShares MSCI Indonesia ETF nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold iShares MSCI Indonesia ETF for 76 Days and Hinge Health Inc. Class A Common Stock for 0 Days on average.
| EIDO | HNGE | |
|---|---|---|
Market Cap | $398.15M | $8.47B |
Volume | 3,087,911 | 1,624,526 |
52-Week High | $19.22 | $105.14 |
52-Week Low | $10.80 | $31.17 |
Typical Hold Time | 76 Days | 0 Days |
Sector | — | Health |
Enterprise Value | — | $8.09B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
EIDO (iShares MSCI Indonesia ETF) trades at $11.71, up 0.34% with bearish technical signals from moving averages and neutral oscillators. The ETF faces weak price action despite trading at a bargain valuation of 8.7x P/E. Recent news highlights foreign capital rotation away from Asian equities and Indonesia's limited benefit from commodity gains, with 44% financials weighting constraining growth potential.
Outlook remains cautious due to technical downtrend and sector concentration risks. The low valuation offers potential value, but persistent weak momentum and limited EPS growth of 5.9% temper upside. Key risks include dependence on financial sector performance and broader Asian market sentiment shifts.
Hinge Health (HNGE) trades at $105.14, up 0.31% on the day and near its 52-week high. The stock shows strong analyst support with a 93.75% buy rating, though the current price exceeds the consensus target of $101.62. Recent earnings beat expectations in two of the last three quarters, with Q3 2026 results due November 2. Fundamentals indicate robust revenue growth projections from $588 million in 2025 to $720 million in 2026, alongside a shift to profitability, but valuation multiples like EV/EBITDA at 82.33 remain elevated.
The outlook is cautiously optimistic given projected profitability and expansion into migraine and GI care, but risks include high insider selling, competitive pressures, and the stock's premium valuation. Execution on growth targets and Q3 earnings will be critical for sustaining momentum.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About iShares MSCI Indonesia ETF
The fund generally will invest at least 80% of its assets in the component securities of the underlying index and in investments that have economic characteristics that are substantially identical to the component securities of the underlying index. The index is a free float-adjusted market capitalization-weighted index that is designed to measure the performance of the large-, mid- and small-capitalization segments of the equity market in Indonesia. The fund is non-diversified.
Read more on EIDO →About Hinge Health Inc. Class A Common Stock
Hinge Health Inc. operates a digital musculoskeletal (MSK) care platform that delivers exercise therapy for joint and muscle conditions through health plans and employers. Its Precision Motion Technology combines wearable sensors and computer vision to guide patients through clinician-directed physical therapy remotely.
Read more on HNGE →
